Montelukast Teva (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as a dosage form for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children. GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene‑blocking agent used in the management of several respiratory conditions. - Asthma: improves control of chronic airway inflammation and reduces frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes caused by seasonal or perennial allergens. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: symptoms of cold or flu‑like illness. - Abdominal pain: intermittent discomfort in the stomach area. - Cough: non‑productive cough episodes. - Diarrhoea: loose stools occurring occasionally. - Rash: mild skin redness or itching.

Serious or Rare Side Effects: - Neuropsychiatric events: agitation, anxiety, depression or suicidal thoughts. - Allergic reactions: hives, swelling of face or throat, difficulty breathing. - Liver enzyme elevation: abnormal liver function test results. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following safety measures. - Pregnancy: discuss potential risks with a healthcare professional, as safety data are limited. - Breastfeeding: evaluate benefits versus possible exposure to the infant. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant psychiatric conditions: monitor for mood changes or suicidal ideation. - Drug interactions: review all current medications for possible interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring attention to the interaction severity.

Major Interactions (Avoid): - Phenobarbital or rifampin: may reduce montelukast plasma concentrations, decreasing efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole): could increase exposure, raising risk of adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: occasional reports of altered INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilator effect may enhance symptom control. - Other leukotriene modifiers: combined use may increase side‑effect burden without added benefit.